Primary Progressive Multiple Sclerosis Under Anti-TNFα Treatment: A Case Report

Journal of Central Nervous System Disease

Case Report

Francesco Aruta¹  Lucia Ruggiero¹  Raffaele Dubbioso¹  Emanuele Spina¹  Stefano Tozza¹  Fiore Manganelli¹  Aniello Iovino²  Rosa Iodice³ 

[1] Department of Neuroscience, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy;Department of Neuroscience, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy;Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy;Department of Neuroscience, Reproductive Sciences and Odontostomatology, University Federico II of Naples, Naples, Italy;IRCCS SDN, Napoli, Naples, Italy;

关键词: Multiple sclerosis;    adalinumab;    anti-TNFα;    demyelinating disease;   

DOI  :  10.1177/1179573520973820

 received in 2020-06-28, accepted in 2020-10-24,  发布年份 2020

来源: Sage Journals

【 摘 要 】

Antagonists of tumour necrosis factor α (TNFα) are a common therapeutic choice for autoimmune diseases. Although they are effective and relatively safe, an increasing number of immune-mediated adverse events have been reported. Among these, neurological adverse effectsm such as consisting of demyelinating events in the central and peripheral nervous system were described. Demyelination of the central nervous system is a rare complication after treatment with TNFα antagonists. Here, we report a case of multiple sclerosis under treatment with TNFα antagonists and discuss its etiopathogenesis. This 45-year-old female patient developed signs and symptoms suggestive of primary progressive multiple sclerosis during treatment with adalinumab for nodular cystic acne, and magnetic resonance imaging of the patient showed typical lesions of demyelinating disease.

【 授权许可】

CC BY-NC   
© The Author(s) 2020